.
MergerLinks Header Logo

New Deal


Announced

Granite Creek Capital Partners invested in Royal Biologics.

Financials

Edit Data
Transaction Value-
Consideration Type-
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

stem cells

Acquisition

United States

Private

Biotechnology

Private Equity

Synopsis

Edit

Granite Creek Capital Partners, a private investment firm based in Chicago, invested in Royal Biologics, a medical device company focused on the growing regenerative medicine sector. The company, a leading manufacturer and distributor of devices used in stem cell and other surgical procedures, develops, licenses, produces and distributes biologics, orthobiologics and orthopedic implant products. Financial terms were not disclosed. Salvatore Leo and Demetri Soteropoulos, the founders and leaders of Royal Biologics, have built an exceptional business that stands out for its innovations and service,” said Mark Radzik, Partner at Granite Creek. “We are proud to partner with such a results-driven organization and look forward to supporting the company’s continued investments in its product portfolio, distribution network, and management team as it reaches its next stage of growth.”

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US